KZIA vs. COCP, RLYB, ERNA, ABP, EDSA, MBRX, UBX, MEIP, UPXI, and EQ
Should you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Cocrystal Pharma (COCP), Rallybio (RLYB), Eterna Therapeutics (ERNA), Abpro (ABP), Edesa Biotech (EDSA), Moleculin Biotech (MBRX), Unity Biotechnology (UBX), MEI Pharma (MEIP), Upexi (UPXI), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry.
Kazia Therapeutics vs.
Kazia Therapeutics (NASDAQ:KZIA) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Kazia Therapeutics has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.
In the previous week, Cocrystal Pharma had 4 more articles in the media than Kazia Therapeutics. MarketBeat recorded 4 mentions for Cocrystal Pharma and 0 mentions for Kazia Therapeutics. Cocrystal Pharma's average media sentiment score of 0.93 beat Kazia Therapeutics' score of 0.00 indicating that Cocrystal Pharma is being referred to more favorably in the news media.
Kazia Therapeutics received 56 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 77.42% of users gave Cocrystal Pharma an outperform vote while only 52.98% of users gave Kazia Therapeutics an outperform vote.
Kazia Therapeutics has higher revenue and earnings than Cocrystal Pharma.
Kazia Therapeutics presently has a consensus price target of $57.50, indicating a potential upside of 1,506.15%. Cocrystal Pharma has a consensus price target of $7.00, indicating a potential upside of 379.45%. Given Kazia Therapeutics' higher possible upside, analysts clearly believe Kazia Therapeutics is more favorable than Cocrystal Pharma.
30.9% of Kazia Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 1.0% of Kazia Therapeutics shares are owned by company insiders. Comparatively, 28.1% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Kazia Therapeutics' return on equity of 0.00% beat Cocrystal Pharma's return on equity.
Summary
Kazia Therapeutics beats Cocrystal Pharma on 9 of the 13 factors compared between the two stocks.
Get Kazia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kazia Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KZIA) was last updated on 5/24/2025 by MarketBeat.com Staff
Buy KZIA Stock Free KZIA Stock Alerts